Insights / Members-only The evolution of target validation in drug discovery Dr. Cathy Tralau-Stewart, chief scientific officer at ValiRx, describes the evolution of target validation in drug discovery, ways of tackling project attrition, and the role of human organoid models in future drug discovery strategies. By Cathy Tralau-Stewart / 11 Apr 2023
